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Abstract
Background: Helicobacter pylori infection is the most important risk factor for gastric cancer, for which eradication
therapy is commonly performed. However, gastric cancer is sometimes discovered after successful eradication of H.
pylori. Much evidence indicates that diabetes mellitus (DM) is a risk factor for gastric cancer. The incidence and
characteristics of gastric cancer diagnosed after H. pylori eradication in DM patients remain to be determined.
Methods: We followed the clinical course of patients who underwent H. pylori eradication therapy at our
institution. Endoscopy was performed before and after eradication. We compared the incidence and clinical
characteristics of gastric cancer arising in DM and non-DM patients.
Results: In total, 965 patients who underwent successful eradication (518 DM and 447 non-DM patients) were
followed-up for an average of 4.5 years. During the follow-up period, 21 gastric cancers were diagnosed (12 in DM
patients and 9 in non-DM patients). The incidence of gastric cancer after eradication was not significantly different
between DM and non-DM patients (0.485 and 0.482 %/year, respectively). There was no significant difference in the
pathology, diameter, depth, location, or treatment of gastric cancer between patients with and without DM.
Conclusion: The incidence and characteristics of gastric cancer occurring after H. pylori eradication were
comparable between DM and non-DM patients.
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Background
Gastric cancer is a major cause of cancer death world-
wide. Infection with Helicobacter pylori (H. pylori), first
isolated by Warren and Marshall [1], together with the
subsequent changes in the gastric mucosa, is the most
important risk factor for gastric cancer [2–5]. Previous
reports have suggested that H. pylori eradication re-
duces the incidence of gastric cancer [6–8]. Therefore,
eradication therapy is now commonly performed. How-
ever, gastric cancer is occasionally discovered after suc-
cessful H. pylori eradication, and investigations of the
risk factors for, and characteristics of, gastric cancer
after eradication have been conducted [9, 10].
The infection–inflammation–cancer axis is widely ac-
cepted, based in part on epidemiological and basic inves-
tigations of H. pylori [11]. On the other hand, evidence
is accumulating that diseases associated with adult life-
style factors—e.g., diabetes mellitus (DM)—enhance the
risk of malignancies, including gastric cancer [12, 13].
Thus, it is possible that the presence of DM might affect
the gastric carcinogenesis such as incidence and histo-
logical characteristics of gastric cancer after H. pylori
eradication.
However, few studies have examined the inhibitory ef-
fect of H. pylori eradication therapy on gastric cancer in
DM patients. In this study, we investigated the incidence
and characteristics of gastric cancer diagnosed after H.
pylori eradication in DM patients.* Correspondence: sakitani-tky@umin.ac.jp
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To evaluate the incidence and characteristics of gastric
cancer diagnosed after H. pylori eradication in DM pa-
tients, 991 patients who underwent successful H. pylori
eradication therapy at our institution between January
1996 and March 2013 and were followed up for over
6 months (the follow-up period was defined as the
period from the day of commencement of eradication
therapy to the day of the last endoscopy performed at
our institution) were analyzed retrospectively. Then, we
excluded patients who met the following criteria: i) those
in whom endoscopy before eradication was not con-
ducted at our institution (n = 18) and ii) those with a
previous history of gastrectomy (n = 8). Therefore, a total
of 965 patients were included in the analysis.
Patients were divided into DM and non-DM groups.
DM was diagnosed according to the 2010 Japan Diabetes
Society (JDS) criteria [14]. The diagnoses of hypertension
(HT), hyperlipidemia (HL), and hyperuricemia (HU) were
based on the need for medical treatment. The study de-
sign was approved by the Ethics Committee at the
Institute for Adult Diseases, Asahi Life Foundation
and conformed to the Declaration of Helsinki. The
patients’ records were anonymized prior to analysis.
Written informed consent was obtained from all
participants.
H. pylori eradication therapy
H. pylori infection was defined by a positive result for at
least one of the following: rapid urease test (Helicocheck,
Otsuka Pharmaceuticals, Tokyo, Japan), serological testing
for anti-H. pylori IgG, 13C-urea urea breath test, or patho-
logical analysis by hematoxylin and eosin or Giemsa stain-
ing. Patients in whom H. pylori infection was confirmed
underwent eradication therapy. Patients in whom eradi-
cation therapy had failed received additional treatment:
the first-line regimen comprised a proton pump inhibi-
tor (PPI), amoxicillin, and clarithromycin [15]; the
second-line regimen comprised a PPI, amoxicillin, and
metronidazole; and the third-line regimen comprised a
PPI, amoxicillin, and sitafloxacin [16]. The success or
failure of eradication therapy was determined by a 13C-urea
breath test performed at least 4 weeks after treatment.
Endoscopy
At our institution, patients who receive eradication therapy
are recommended to undergo esophagogastroduodeno-
scopy annually. The upper gastrointestinal endoscopies
were performed by experienced endoscopists. Gastric
mucosal atrophy was evaluated using the endoscopic scale
described by Kimura and Takemoto [17], which has been
reported to concord with the histological results [18]. Pa-
tients were classified into three groups according to their
endoscopic atrophic gastritis grade: the mild (C-I and
C-II), moderate (C-III and O-I), and severe atrophic
gastritis (O-II and O-III) groups.
Gastric cancer determination
Biopsy specimens were taken from the neoplastic lesion,
and the final diagnosis of gastric cancer was based on
the pathology results. Gastric cancers were classified
pathologically according to Lauren’s classification as in-
testinal or diffuse type [19]. A lesion identified by endos-
copy prior to eradication was not counted as gastric
cancer after eradication in this study.
Statistical analysis
All statistical analyses were performed using the JMP10
software (SAS Institute, Cary, NC, USA). Welch’s t-test
was used to compare the means of continuous variables.
Comparisons of nominal variables were performed by χ2
test or Fisher’s exact test, as appropriate. The incidence
of gastric cancer in patients with and without DM was
evaluated using the Kaplan–Meier method, and the stat-
istical significance of the differences was evaluated by
log-rank test. The diagnosis of gastric cancer was the
primary endpoint, and data were censored at the last en-
doscopy. The risk of gastric cancer after eradication was
assessed using Cox’s proportional-hazards model. Since
no gastric cancer was detected in the mild atrophic gas-
tritis group, this group served as the control. Odds ratios
(OR) with 95 % confidence intervals (CI) were used as a
measure of association and were adjusted using uncon-
ditional logistic regression models. A two-sided p-value
of less than 0.05 was considered to indicate statistical
significance.
Results
Baseline characteristics of the patients
The baseline characteristics of the patients are provided in
Table 1. In total, 965 patients (729 males and 236 females,
mean age 62.9 years, and mean body mass index (BMI)
23.2 kg/m2) underwent successful H. pylori eradication
therapy as the first-, second-, and third-line regimens in
782 (81.0 %), 178 (18.4 %), and 5 (0.52 %) patients, re-
spectively. The 965 patients comprised 518 DM patients
(13 type 1 DM and 505 type 2 DM patients) and 447 non-
DM patients. Patients were followed-up for up to
16.2 years (mean 4.5 years). In terms of the endoscopic
atrophic gastritis grade, 173 (17.9 %), 422 (43.7 %), and
370 (38.3 %) patients were categorized as having mild,
moderate, and severe atrophic gastritis, respectively.
Non-DM patients who underwent eradication therapy
were significantly younger than DM patients (60.7 and
64.8 years, respectively). The mean follow-up period
(4.18 years for non-DM patients and 4.78 years for DM
patients) and mean endoscopy interval (1.37 years for
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non-DM patients and 1.61 years for DM patients) of the
non-DM patients were significantly shorter than those
of the DM patients. The mean BMI (23.1 kg/m2 for
non-DM patients and 23.4 kg/m2 for DM patients) was
not significantly different between non-DM and DM pa-
tients. The proportion of patients who received medica-
tions for HT and HL was higher in DM than in non-DM
patients.
Incidence and characteristics of gastric cancer after
H. pylori eradication
During the follow-up period, 21 gastric cancers [9 in
non-DM patients (0.482 %/year) and 12 in DM patients
(0.485 %/year)] were diagnosed after H. pylori eradica-
tion (Table 2). No gastric cancer was found in the mild
atrophic gastritis group, while 8 (38.1 %) gastric cancers
were diagnosed in the moderate atrophic gastritis group
and 13 (61.9 %) in the severe atrophic gastritis group.
Among these 21 gastric cancers, there were no cardiac
cancers. Eleven (52.4 %) gastric cancers had a depth of in-
vasion limited to the mucosa; the remainder [10 (47.6 %)]
exhibited submucosal or deeper invasion.
The mean age (69.4 years for non-DM patients and
70.6 years for DM patients), the proportion of males
(77.8 % for non-DM patients and 91.7 % for DM patients),
mean follow-up duration (4.59 years for non-DM patients
and 3.95 years for DM patients), mean endoscopy interval
(1.93 years for non-DM patients and 1.62 years for DM
patients), mean BMI (23.4 kg/m2 for non-DM patients
and 22.6 kg/m2 for DM patients) and atrophic gastritis
grade were not significantly different between the gastric
cancer patients with versus without DM.
In total, 16 (76.2 %) intestinal-type gastric cancer and
5 (23.8 %) diffuse-type gastric cancer cases were diag-
nosed. Among the non-DM gastric cancer patients,
88.9 % (8/9) were of the intestinal type, compared with
66.7 % (8/12) of the DM gastric cancer patients. Regard-
ing gastric cancer treatment modalities, 11 (52.4 %) pa-
tients underwent curative endoscopic treatment. The
remaining 10 (47.6 %) patients received curative surgi-
cal treatment. There were no significant differences in
the pathology, diameter (22.1 mm for non-DM patients
and 25.0 mm for DM patients), depth, location, or
treatment of the gastric cancers between patients with
and without DM.
Kaplan–Meier analysis of the proportions of patients
free of gastric cancer after H. pylori eradication with and
without DM is shown in Fig. 1. No significant difference
was found in the incidence of gastric cancer after eradi-
cation between non-DM and DM patients by log-rank
test (p = 0.8754).
Risk factors for gastric cancer after H. pylori eradication
We next analyzed the risk factors for gastric cancer after
H. pylori eradication using Cox’s proportional hazards
model (Table 3). Age, sex, BMI, DM, HT, HL, and HU
were not found to be risk factors for gastric cancer after
H. pylori eradication in either univariate or multivariate
analysis. Severe atrophic gastritis before eradication was
identified as a significant risk factor for gastric cancer
after H. pylori eradication in the multivariate analysis
(OR 2.56, 95 % CI 1.03–6.77, p = 0.0424), in accordance
with a previous report [9].
Table 1 Characteristics of patients with and without DM who underwent H. pylori eradication therapy
Total (n = 965) Non-DM (n = 447) DM (n = 518) p
Mean age (range), years 60.7 (27–84) 64.8 (30–86) <0.0001*
Sex, n (%) <0.0001*
Female 139 (31.1 %) 97 (18.7 %)
Male 308 (68.9 %) 421 (81.3 %)
Mean follow-up period (range), years 4.18 (0.54–13.2) 4.78 (0.68–16.2) 0.0006*
Mean endoscopy interval (range), years 1.37 (0.40–8.38) 1.61 (0.34–8.08) <0.0001*
Mean body mass index (range), kg/m2 23.1 (14.8–34.9) 23.4 (15.9–32.3) 0.1452
Atrophic gastritis grade, n (%) 0.0011*
Mild 95 (21.3 %) 78 (15.1 %)
Moderate 207 (46.3 %) 215 (41.5 %)
Severe 145 (32.4 %) 225 (43.4 %)
Hypertension, n (%) 99 (22.1 %) 244 (47.1 %) <0.0001*
Hyperlipidemia, n (%) 89 (19.9 %) 220 (42.5 %) <0.0001*
Hyperuricemia, n (%) 32 (7.16 %) 48 (9.27 %) 0.236
DM diabetes mellitus
*Statistically significant (p < 0.05)
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Fig. 1 Kaplan–Meier analysis of the proportion of patients with and without diabetes mellitus (DM) free from gastric cancer after H. pylori eradication
therapy. Gastric cancer was diagnosed in nine non-DM patients and 12 DM patients during the follow-up period (p =0.8754, log-rank test)
Table 2 Characteristics of gastric cancer in patients with and without DM after H. pylori eradication therapy
Total (n = 21) Non-DM (n = 9) DM (n = 12) p
Mean age (range), years 69.4 (56–80) 70.6 (60–78) 0.7137
Sex, n (%) 0.5533
Female 2 (22.2 %) 1 (8.33 %)
Male 7 (77.8 %) 11 (91.7 %)
Mean follow up period (range), years 4.59 (1.03–11.8) 3.95 (0.95–7.15) 0.6990
Mean endoscopy interval (range), years 1.93 (0.99–4.06) 1.62 (0.70–2.95) 0.2527
Mean body mass index (range), kg/m2 23.4 (19.5–27.5) 22.6 (19.0–30.1) 0.5534
Atrophic gastritis, n (%) 0.2030
Mild 0 0
Moderate 5 (55.6 %) 3 (25.0 %)
Severe 4 (44.4 %) 9 (75.0 %)
Pathology, n (%) 0.3383
Intestinal type 8 (88.9 %) 8 (66.7 %)
Diffuse type 1 (11.1 %) 4 (33.3 %)
Diameter, mm 22.1 (3–70) 25.0 (5–60) 0.7543
Depth, n (%) 0.2562
Mucosa 6 (66.7 %) 5 (41.7 %)
Submucosa and deeper 3 (33.3 %) 7 (58.3 %)
Location, n (%) 0.7332
Upper third 3 (33.3 %) 2 (16.7 %)
Middle third 3 (33.3 %) 5 (41.7 %)
Lower third 3 (33.3 %) 5 (41.7 %)
Treatment, n (%) 0.3869
Endoscopic 6 (66.7 %) 5 (41.7 %)
Surgery 3 (33.3 %) 7 (58.3 %)
DM diabetes mellitus
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Discussion
In this study, we aimed to elucidate the incidence and
characteristics of gastric cancer after H. pylori eradica-
tion therapy in DM patients. Our results indicated that
the incidence and characteristics of gastric cancer devel-
oping after H. pylori eradication therapy were not sig-
nificantly different between DM and non-DM patients.
The incidence of gastric cancer after eradication was
0.48 %/year and the mean age of the patients 62 years.
The incidence and mean age are in agreement with
those reported by Ogura et al. (0.46 %/year and 62 years,
respectively) [6]. Kamada et al. reported that severe mu-
cosal atrophy in the corpus is a risk factor for gastric
cancer after eradication [9]. This study also showed that
severe atrophic gastritis before eradication is the risk for
gastric cancer suggesting follow-up endoscopy of pa-
tients with severe atrophic gastritis is necessary.
The prevalence of DM is rapidly increasing, and sev-
eral studies have focused on the interaction of DM with
H. pylori infection and the gastric cancer axis [20–22].
The prevalence of H. pylori infection in DM patients is
reportedly higher than that in non-DM patients [23].
Sekikawa et al. reported that open-type atrophic gastritis
is found more frequently in DM patients than in non-
DM patients (33.4 % (50/148) and 21.1 % (274/1301),
respectively); moreover, the presence of DM increased
the risk of development of early gastric cancer. In the
present study, the presence of DM did not increase the
incidence of gastric cancer after H. pylori eradication
therapy. It is possible that DM acts synergistically with
consistent H. pylori infection to increase the risk of gas-
tric cancer, as reported previously [24], and that the
presence of DM after H. pylori eradication therapy might
not enhance the risk of gastric cancer.
Other possible risk factors for gastric cancer (such as
smoking and high salt intake) have been reported to in-
crease gastric cancer risk synergistically with H. pylori
infection [25, 26]. A prospective study conducted in
Japan (the Hisayama study) found that the combination
of smoking and H. pylori infection increased the risk of
gastric cancer more than did smoking or H. pylori infec-
tion alone [25]. The Hisayama study also found a signifi-
cant association between high salt intake and gastric
cancer in a population with atrophic gastritis and H. pylori
infection [26].
In the present study, the pathological features of gas-
tric cancer after eradication were not significantly differ-
ent between DM and non-DM patients. This finding is
in line with a previous report that there is no significant
difference in the histopathological differentiation of
Table 3 Cox’s proportional hazards model for factors associated with the incidence of gastric cancer after H. pylori eradication
Factor Univariate p Multivariate p
OR (95 % CI) OR (95 % CI)
Age (years) 1.01 (0.96–1.06) 0.6248 1.00 (0.94–1.05) 0.9446
Sex
Female 1
Male 1.82 (0.61–7.78) 0.3030 2.13 (0.67–9.46) 0.1914
Body mass index kg/m2) m2) 1.02 (0.83–1.13) 0.7880 1.01 (0.83–1.15) 0.8264
Diabetes mellitus (DM)
Non-DM 1
DM 0.93 (0.39–2.30) 0.8756 0.64 (0.25–1.66) 0.3530
Hypertension (HT)
Non-HT 1
HT 1.40 (0.57–3.31) 0.4459 1.36 (0.53–3.36) 0.4985
Hyperlipidemia (HL)
Non-HL 1
HL 1.15 (0.43–2.83) 0.7600 1.17 (0.42–2.99) 0.7485
Hyperuricemia (HU)
Non-HU 1
HU 0.62 (0.03–3.05) 0.6295 0.43 (0.02–2.24) 0.3811
Atrophic gastritis
Mild-Moderate 1
Severe 2.63 (1.10–6.67) 0.0280* 2.56 (1.03–6.77) 0.0424*
OR odds ratio; CI confidence interval
*Statistically significant (p < 0.05)
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gastric cancer in patients with versus without DM [27].
The proportion of those with intestinal-type gastric
cancer after eradication (76.2 %, 16/21) in this study is
in agreement with that reported by Kamada et al.
(75.0 %, 15/20) [9].
There were several limitations to our study. First, it
was a retrospective cohort design; therefore, further pro-
spective and longer-term studies are required. Second,
several possible risk factors for gastric cancer—such as
smoking, alcohol intake, dietary habits, family history
and H. pylori virulence factors—were not evaluated. Re-
garding lifestyle factors, a previous report showed that
smoking and drinking alcohol were not associated with
the development of gastric cancer after H. pylori eradica-
tion therapy [28].
Conclusion
Our findings indicated that the incidence and character-
istics of gastric cancer after H. pylori eradication therapy
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